Treatment of RMS lines with higher doses of SREBP2 and MVP inhibitors (5–50 μM) promoted oxidative cell death and chemosensitization in combination with actinomycin D. Administration of lFatostatin and lovastatin or fatostatin to RD and RH30 cells produced produced a rapid attenuation of Erk1/2 and Akt1 phosphorylation signaling in RMS lines, and oral administration of lovastatin reduced tumor mass detectable after 4 h of treatment. Here, SREBF2 is linked to neoplasm.